Clinical development failure
LP-10, LP-310, and LP-50 have not yet been approved, so efficacy or safety issues could stop the programs.
- Scope
- Lead pipeline value
- Materiality
- high
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company developing reformulations of existing generic drugs for new therapeutic uses. Its lead programs, LP-10 and LP-310, target hemorrhagic/radiation cystitis and oral lichen planus, while LP-50 is a preclinical bladder-cancer program built on the company’s proprietary epithelial-tissue drug delivery platform.
−946,7 %
−935,2 %
+19,3 %
3.47
3.47
| % | |
|---|---|
| Lead clinical programs | 0% LP-10 and LP-310 are the company’s main development assets targeting unmet-need indications. |
| Preclinical pipeline | 0% LP-50 is an earlier-stage intravesical bladder-cancer program using the same delivery approach. |
| Platform technology | 0% The company’s formulation and delivery platform is designed for epithelial tissues such as bladder, mouth, and colon. |
| Grant-funded research | 100% NIH grant revenue supports ongoing research and development activities. |
Lipella does not yet sell approved products; its current economic “customers” are primarily grant providers and, in the...
- Grant fundersprimary
Government and research grant providers fund development work before product sales exist.
- Specialist physiciansprimary
Urologists, oncologists, and oral medicine specialists would prescribe the therapies if approved.
- Hospitals and treatment centerssecondary
Clinical sites and hospital systems would administer or stock the products in specialty care settings.
- Patients with unmet-need indicationsprimary
Patients with hemorrhagic cystitis, oral lichen planus, or bladder cancer are the eventual end users.
Lipella is headquartered in the United States and its development, patent protection, and clinical activity are...
- •United States is the core operating and clinical market
- •Issued patents extend to Australia, Canada, and Europe
- •Potential future commercialization depends on regulatory approvals
- •No meaningful commercial revenue geography disclosed yet
- •IP protection is important to monetization across major markets
Lipella’s strategy is to reformulate known active ingredients into proprietary therapies for diseases with high unmet...
01
Advance lead clinical programsshort-term
LP-10 and LP-310 are the main value drivers and need clinical proof to reach approval.
02
Protect intellectual propertymedium-term
Patent coverage is central to monetizing reformulated drugs and defending against competitors.
03
Secure funding and extend runwayshort-term
The company is pre-revenue and must finance trials, manufacturing, and regulatory work.
Lipella faces the classic risks of a clinical-stage biotech: trial failure, regulatory setbacks, and ongoing financing...
Regulatory approval risk
Even positive data may not translate into FDA or other approvals, delaying commercialization.
- Scope
- All product candidates
- Materiality
- high
Financing and dilution risk
The company has ongoing losses and will likely need additional capital, which can dilute shareholders.
- Scope
- Capital structure
- Materiality
- high
Nasdaq continued listing risk
The company disclosed noncompliance with certain Nasdaq requirements, which could lead to delisting.
- Scope
- Trading liquidity and valuation
- Materiality
- high
Third-party supply and CRO dependence
Clinical and manufacturing work is outsourced, so vendor delays or failures can slow development.
- Scope
- Trial execution
- Materiality
- medium
Grant revenue recognition
Revenue and operating loss timing
Accrued expenses and service agreements
Liabilities and R&D expense
Going-concern assessment
Disclosure and investor risk assessment
Equity issuance and conversion accounting
Capital structure and per-share metrics
LB PHARMACEUTICALS INC
LBRX · Pharmaceutical Preparations
LISATA THERAPEUTICS, INC.
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Lyell Immunopharma, Inc.
LYEL · Pharmaceutical Preparations
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer.
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
: 28/04/2026